Your browser doesn't support javascript.
loading
Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation.
Maslova, Vera; Demming, Thomas; Pantlik, Robert; Geczy, Tamas; Falk, Peter; Remppis, Bjoern Andrew; Frank, Derk; Lian, Evgeny.
Afiliação
  • Maslova V; Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Demming T; Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Pantlik R; Department of Cardiology, Cardiovascular Center Bad Bevensen, Bad Bevensen, Germany.
  • Geczy T; Department of Cardiology, Cardiovascular Center Bad Bevensen, Bad Bevensen, Germany.
  • Falk P; Department of Cardiology, Cardiovascular Center Bad Bevensen, Bad Bevensen, Germany.
  • Remppis BA; Department of Cardiology, Cardiovascular Center Bad Bevensen, Bad Bevensen, Germany.
  • Frank D; Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Lian E; Department of Internal Medicine III, Cardiology and Angiology, University Hospital Schleswig-Holstein, Kiel, Germany. evgeny.lyan@uksh.de.
Article em En | MEDLINE | ID: mdl-38761295
ABSTRACT

BACKGROUND:

Data about necessity of performing transesophageal echocardiography (TOE) prior to every catheter ablation (CA) of atrial fibrillation (AF) is scarce. We aimed to evaluate the safety of an individualized risk-based approach to TOE with respect to thromboembolic cerebrovascular events (CVE) in patients undergoing CA for AF or left atrial tachycardia (AT).

METHODS:

We performed a retrospective clinical study based on our institutional registry database. Patients undergoing CA for AF or left-sided AT following initial AF ablation at two participating centers were enrolled. Prior to the procedure, patients were scheduled for TOE only if they had a history of thromboembolic stroke, left atrial appendage (LAA) thrombus, or inappropriate anticoagulation regimen in the previous 3 to 4 weeks. The incidence of periprocedural cerebrovascular thromboembolic events was assessed.

RESULTS:

We analyzed 1155 patients (median age 70 years, 54.8% male, 48.1% had persistent AF/AT). In 261 patients, a TOE was performed; in 2 patients (0.7%), an LAA thrombus was detected, which led to cancellation of the catheter ablation; in 894 patients, the TOE was omitted. Of the 1153 (0.35%) patients who underwent ablation, 4 (0.35%) experienced a CVE (one TIA and three strokes). The rate of CVE in our study does not exceed that reported in most multicenter trials. The low event rates limited statistical analysis of possible risk factors for CVE. In all 4 patients with CVE, post-CVE imaging showed the absence of LAA thrombus.

CONCLUSIONS:

An individualized selective approach to TOE before catheter ablation of AF or left AT showed a very low risk of overt intraprocedural thromboembolic events for the population in our study. A further randomized controlled study is needed to determine whether TOE prior to catheter ablation without ICE could be omitted in patients with uninterrupted OAC without previous thromboembolic events or a history of left atrial thrombus.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Interv Card Electrophysiol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Interv Card Electrophysiol Ano de publicação: 2024 Tipo de documento: Article